title: Cataract surgery under systemic infliximab therapy in patients with refractory uveitis associated with Behcet disease.
abstract: OBJECTIVE
  This study is to evaluate the outcome of cataract surgery in patients with refractory uveitis associated with Behçet disease (BD) treated with infliximab.
  
  
  METHODS
  A retrospective study in a university-based tertiary referral center in the period between July 2003 and November 2011.
  
  
  METHODS
  This is a retrospective study of patients with refractory uveitis associated with BD who underwent phacoemulsification cataract surgery under systemic infliximab therapy between July 2003 and November 2011 at King Abdulaziz University Hospital, Riyadh, Saudi Arabia.
  
  
  RESULTS
  Six patients (9 eyes), 5 of which were male and 1 female, were identified in this study. The mean (SD) age and follow-up period were 26.2 (6.6) years (range, 16-36 years) and 51.6 (28.8) months (range, 12.84 months), respectively. All the patients underwent phacoemulsification with intraocular lens implantation. Postoperatively, visual acuity improved in all eyes and was 20/40 or better in 7 eyes (77.8%). In the immediate postoperative period, anterior chamber inflammation ranged from 2+ to 3+ cells. None of the patients developed inflammation relapse postoperatively. The most common postoperative complication was posterior capsular opacification in 5 eyes (55%), 4 of which were managed with neodymium:yttrium-aluminum garnet laser capsulotomy. Three eyes had glaucoma, 2 of which underwent successful glaucoma surgery and one was managed with topical antiglaucoma medications.
  
  
  CONCLUSIONS
  In patients with refractory uveitis associated with BD who are treated with infliximab, cataract surgery is safe and has a good prognosis.
authors: Dr. Abdullah Alfawaz, Department of Ophthalmology, College of Medicine, King Abdulaziz University Hospital, PO Box 245, Riyadh 11411, Saudi Arabia, T: +966114775723, F: +966114775724, abfz22@hotmail.com.
authors: Abdullah
authors: A
authors: Alfawaz
authors: Sultan
authors: S
authors: Alrashidi
authors: Hatem
authors: H
authors: Kalantan
authors: Hani
authors: H
authors: Al-Mezaine
authors: Ahmed M
authors: AM
authors: Abu
mesh_terms: D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000150:complications / Q000188:drug therapy*; D058442:Capsule Opacification / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000150:complications / Q000601:surgery; D006801:Humans; D000069285:Infliximab; D053844:Lasers, Solid-State / Q000627:therapeutic use; D019654:Lens Implantation, Intraocular / Q000009:adverse effects; D008297:Male; D018918:Phacoemulsification / Q000009:adverse effects; D012189:Retrospective Studies; D016896:Treatment Outcome; D014605:Uveitis / Q000188:drug therapy* / Q000209:etiology; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D000069285:Infliximab